Westlake Village, CA (PRWEB) December 11, 2012
Cynvenio Biosystems, Inc., a developer of rare cell isolation technology for the molecular characterization of cancer and individualized applications in medicine, announced today the commercial availability of its new LiquidBiopsy lab service for the recovery and genomic analysis of circulating tumor cells (CTC) directly from whole blood.
“By analyzing DNA mutations that may be present in circulating tumor cells, physicians and researchers can gather real-time molecular information about their patients, which in turn enables earlier intervention, effective patient monitoring over the entire cancer care cycle, and the ability to genetically match patients with targeted treatments that are most effective against their cancer,” said Paul Dempsey, vice president of bioengineering development at Cynvenio.
LiquidBiopsy is a new, highly sensitive platform and associated chemistry to reliably isolate CTCs from whole blood for genomic analysis. In engineered benchmarks, the system delivered consistently high CTC recovery rates of >90% directly from whole blood, with consistently low non-target capture of <90 cells/mL blood - which is at least 2 orders of magnitude higher purity than earlier technologies. With these purity levels and the Cynvenio-designed automated platform that processes multiple 7.5mL blood samples in under 3 hours, CTCs obtained by LiquidBiopsy can be directly sequenced without additional purification or error-inducing sample manipulation such as whole genome amplification.
The LiquidBiopsy lab service offers three core services involving CTC isolation from whole blood:
CTC Sequencing: targeted resequencing with a 50 oncogene panel and more than 2100 mutations surveyed; the turnaround time from sample receipt is seven days.
CTC PCR Analysis: analysis by PCR of 45 cancer mutation hotspots in EFGR, BRAF or KRAS; turnaround time is five days.
CTC Recovery and Enumeration: cytokeratin, DAPI and CD45 staining with scanning report; with optional return of target cells for downstream analysis at customers’ lab; turnaround in three days.
The companion LiquidBiopsy sample collection kit contains everything necessary for the blood draw and sample prep, including pre-paid FedEx shipping materials and easy to follow instructions. LiquidBiopsy samples do not need to be refrigerated, either during storage or transit to the lab in Westlake Village, CA.
The CTC molecular analysis can be performed by Cynvenio, or, optionally, the target CTCs can be stained and returned to the ordering customer with a scanning/enumeration report for further study and analysis.
“We’re excited to be able to offer our CTC service directly to physicians and oncology researchers,” said André de Fusco, president and CEO of Cynvenio. “We look forward to supporting our customers in the development of companion diagnostics and identification of markers for new drug development. The LiquidBiopsy service puts cutting-edge CTC technology within every lab’s reach to deliver the promise of personalized medicine.”
Cynvenio’s automated CTC isolation platform and sequencing lab has been available to in-house customers such as pharmaceutical companies since earlier this year. The new LiquidBiopsy lab is expected to complete CLIA certification in early 2013.
About Cynvenio Biosystems, Inc.
Cynvenio has developed the LiquidBiopsy platform, a high-performance rare cell isolation system that enables the mutational profiling of circulating tumor cells obtained from a simple, minimally invasive blood draw. Cynvenio’s mission in oncology is to develop the tools for the early detection of disease, to enable longitudinal patient monitoring in support of better treatment decisions, and to facilitate the identification of genetically matched therapeutic solutions. Cynvenio is based in Westlake Village, California, and is privately held. Find out more about the company here: http://www.cynvenio.com and http://www.liquidbiopsy.com.
LiquidBiopsy is a registered trademark of Cynvenio Biosystems, Inc.